Wockhardt (WOCKPHARMA) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
10 Aug, 2026Executive summary
Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Results reviewed by Audit Committee and subjected to limited review by statutory auditors.
Financial highlights
Consolidated revenue from operations for Q1 FY27 was ₹929 crore, up from ₹738 crore in Q1 FY26 and ₹965 crore in Q4 FY26.
Consolidated net profit after tax for Q1 FY27 was ₹107 crore, compared to a net loss of ₹108 crore in Q1 FY26 and profit of ₹164 crore in Q4 FY26.
Standalone revenue from operations for Q1 FY27 was ₹561 crore, up from ₹413 crore in Q1 FY26 and ₹516 crore in Q4 FY26.
Standalone net profit after tax for Q1 FY27 was ₹107 crore, compared to ₹69 crore in Q1 FY26 and ₹167 crore in Q4 FY26.
Total comprehensive income on a consolidated basis for Q1 FY27 was ₹121 crore, up from ₹40 crore in Q1 FY26.
Outlook and guidance
The company continues to operate exclusively in the pharmaceutical segment.
Latest events from Wockhardt
- Zaynich gains US and India approval, targeting $1.5–$2B global peak sales as growth accelerates.WOCKPHARMA
Status update - Revenue and profit surged year-over-year, with fund-raising plans and US exit impacting results.WOCKPHARMAQ4 2026
- Q3 FY26 saw revenue and profit growth, US business exit, and regulatory-driven exceptional charges.WOCKPHARMAQ3 2026
- Q2 FY26 profit rebounded to ₹82 crore despite a ₹97 crore US exit loss; focus shifts to core markets.WOCKPHARMAQ2 25/26
- Q1 FY26 saw flat revenue, a major US exit, and a net loss driven by a ₹97 crore impairment.WOCKPHARMAQ1 25/26
- Q2 FY25 saw higher revenues, reduced losses, and a ₹1,000 crore QIP to boost capital.WOCKPHARMAQ2 24/25
- Standalone profit achieved and consolidated losses reduced amid strong revenue growth.WOCKPHARMAQ1 24/25
- Q3 FY25 saw Wockhardt return to consolidated profit and complete a major Rs 1,000 crore QIP.WOCKPHARMAQ3 24/25
- Wockhardt's FY25 loss narrowed sharply on higher revenue and new capital raised.WOCKPHARMAQ4 24/25